NCT06631417

A Study in Healthy People to Test How 2 Different Doses of BI 1291583 Are Taken up in the Body When Given in 3 Different Formulations

A Trial to Investigate Relative Bioavailability of Three Different BI 1291583 Formulations Following Oral Administration at Two Dose Levels to Healthy Subjects (an Open-label, Randomised, Single-dose, Three-period Crossover Trial Consisting of 2 Parts)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The main objective of this trial is to investigate the relative bioavailability of two different formulations of BI 1291583 (test formulations) compared to BI 1291583 reference formulation administered at two different dose levels.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	BI 1291583	formulation 1
DRUG	BI 1291583	formulation 2
DRUG	BI 1291583	formulation 3

Timeline

• Start date: 2024-10-22
• Primary completion: 2025-01-10
• Completion: 2025-05-14
• First posted: 2024-10-08
• Last updated: 2025-08-13

Locations

1 site across 1 country: Germany